L-CRISPR / Cas9 system based on parainfluenza virus type 5 L strain PIV5-L and application of L-CRISPR / Cas9 system
By inserting the Cas9 gene between the HN and L genes of the PIV5-L of the parainfluenza virus type 5 L strain PIV5-L, the L-CRISPR/Cas9 system was constructed, and the problem of difficulty in expression of the CRISPR-Cas9 system was solved, and efficient knocking of target cell genes was achieved Extra-multiple gene expression improves delivery efficiency and safety.
Patent Information
- Application Number
- CN202411274104.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-12
- Publication Date
- 2024-12-03
AI Technical Summary
The CRISPR-Cas9 system has difficulty in expression in vitro or in vivo applications, especially due to the inefficiency of delivery caused by excessive length of the Cas9 gene, as well as the potential risks and cellular damage problems caused by different vectors.
Using the Cas9 expression vector based on the PIV5-L of the parainfluenza virus type 5 L strain, the L-CRISPR/Cas9 system was constructed by inserting the Cas9 gene between the HN and L genes, and combining the GFP gene to improve expression efficiency and visual infection efficiency. Achieve efficient knockout of targeted genes.
The effective expression of Cas9 protein and the efficient delivery of the CRISPR system are achieved, ensuring knockout or downregulation of target genes in target cells, and avoiding the impact of excessive expression levels on cells, improving the safety and efficiency of vectors.
Smart Images

Figure CN119061066A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of genetic engineering technology, and in particular to a Cas9 expression vector based on parainfluenza virus type 5 L strain PIV5-L, an L-CRISPR / Cas9 system and applications. Background Art
[0002] Clustered regularly interspaced shortpalindromic repeats (CRISPR) were discovered in bacteria and archaea in the 1980s. They are a repetitive DNA segment in bacterial genes and are related to bacterial innate immunity. CRISPR-associated protein (Cas) has nuclease function. Under the guidance of RNA transcribed by CRISPR (this sequence was gradually optimized in subsequent application research and named single guide RNA (sgRNA), it cuts double-stranded DNA complementary to its transcribed RNA to defend against invasion from viruses or bacteriophages in ancient organisms and bacteria. The Cas proteins discovered so far include Cas1 to Cas10 and relatively rare types such as Cas8a1, Cas12a, and Cas13a. Among them, Cas9 protein has received the most attention due to its simple and efficient gene cutting characteristics. With further research, the CRISPR system has gradually developed into a gene editing technology and completed the application of genome editing in mammalian cells. Among them, the CRISPR system established with Cas9 protein is the most widely used, called CRISPR-Cas9 system. The CRISPR / Cas9 system relies on the complementary base pairing between sgRNA and the target DNA site containing the adjacent protospacer adjacent motif (PAM) sequence, and then the Cas9 endonuclease cuts the genome to cause a double-strand break (Double-strand break, DSB), and then complete the knockout of the target gene in the gene repair process, which can effectively achieve gene editing.
[0003] However, in the in vitro or in vivo application of CRISPR-Cas9 system, safe, efficient and universal delivery platform is still the biggest challenge. At present, there are many vectors for in vitro and in vivo delivery of CRISPR system: including viral vectors, such as adeno-associated virus (AAVs), lentivirus (LV), etc.; and non-viral delivery methods, such as electroporation, microinjection, nanoparticles, etc. However, different vectors have their corresponding shortcomings. For example, there is a potential risk of gene integration into host chromosomes of lentiviral vectors, and electroporation is more harmful to cells. Even if there are integration-defective lentiviral vectors, their expression efficiency is low. At the same time, due to the long length of Cas9 gene, the efficiency of delivery process is low, so the expression of CRISPR-Cas9 system is still difficult. Summary of the invention
[0004] The purpose of the present invention is to solve the problem of difficulty in expressing the CRISPR-Cas9 system in the prior art, and to provide an L-CRISPR / Cas9 system and application based on parainfluenza virus type 5 L strain PIV5-L.
[0005] To solve the above technical problems, the technical solution adopted by the present invention is as follows: a Cas9 expression vector based on parainfluenza virus type 5 L strain PIV5-L, the Cas9 expression vector is a recombinant plasmid pB-L-Cas9 (HN-L), and the sequence is shown in SEQ ID NO.73.
[0006] Preferably, it also contains a GFP gene, and the Cas9 expression vector is a recombinant plasmid pB-L-GFP-Cas9 (HN-L), and the sequence is shown in SEQ ID NO.74.
[0007] The present invention also provides an L-CRISPR / Cas9 system based on parainfluenza virus type 5 L strain PIV5-L, comprising sgRNA targeting a target gene and the above-mentioned Cas9 expression vector.
[0008] The present invention also provides an application of the L-CRISPR / Cas9 system in constructing gene knockout cells, wherein the sgRNA targeting the target gene is inserted between the HN gene and the L gene of the Cas9 expression vector by a seamless cloning method to construct a recombinant plasmid L-sgRNA-Cas9 or L-GFP-sgRNA-Cas9; the recombinant plasmid L-sgRNA-Cas9 or L-GFP-sgRNA-Cas9 is transfected into BHK-optT7 cells to complete the packaging of the recombinant virus; the packaged recombinant virus is used to infect the target cells, thereby delivering the CRISPR system and knocking out the target gene in the target cell.
[0009] Preferably, the sgRNA is sgCasp7; the sgCasp7 targets the Caspase7 gene in the B lymphoma cell line DG75; the sequence of the sgCasp7 is shown in SEQ ID NO.46.
[0010] Preferably, the sgRNA is sgMCT1; the sgMCT1 targets the MCT1 gene in the B lymphoma cell line LCL; the sequence of the sgMCT1 is shown in SEQ ID NO.45.
[0011] Preferably, pB-L-GFP-Cas9 (HN-L) is used as a vector, and the GFP gene is replaced by sgRNA through seamless cloning to construct a recombinant plasmid L-sgRNA-Cas9.
[0012] Further preferably, pB-L-GFP-Cas9 (HN-L) is used as a vector, and the sgRNA is inserted between the GFP gene and the Cas9 gene by seamless cloning to construct the recombinant plasmid L-GFP-sgRNA-Cas9.
[0013] Further preferably, the 5' end of the sgRNA is connected to the transcription termination start sequence of PIV5, and the transcription termination start sequence of PIV5 is shown in SEQ ID NO.75.
[0014] The beneficial effects of the present invention are:
[0015] (A) The present invention inserts the Cas9 gene between the HN gene and the L gene, between the SH gene and the HN gene in the PIV5-L viral genome, or replaces the SH gene with the Cas9 gene. Cas9 can be effectively expressed at these three positions, and these three recombinants have almost no effect on viral replication and packaging. The protein expression level is exogenous gene replacing SH> exogenous gene located between SH and HN genes> exogenous gene inserted between HN and L genes. Therefore, in order to avoid the possibility that the high expression level of the Cas9 gene may cause an increase in the off-target rate and affect cell survival, the present invention chooses to place the Cas9 gene between the HN and L genes.
[0016] (ii) Furthermore, the present invention inserts GFP and Cas9 genes between the HN and L genes, and the constructed L-GFP-Cas9 recombinant virus can express GFP and Cas9 proteins, indicating that PIV5-L can utilize its own transcriptional signals to efficiently express multiple exogenous genes at the same time, and is a very potential exogenous gene expression vector.
[0017] (III) Finally, the present invention constructs an L-sgRNA-Cas9 integrated system by inserting sgRNA and Cas9 genes between the HN gene and the L gene of the parainfluenza virus type 5 L strain PIV5-L genome; and constructs L-GFP-sgRNA-Cas9 using the green fluorescent protein gene as a reporter gene to achieve visualization of infection efficiency. The present invention uses the Caspase7 gene as the target gene, constructs L-sgCaspase7-Cas9 and L-GFP-sgCaspase7-Cas9 systems, both of which have knockout effects on the Caspase7 gene in DG75 cells; uses the MCT1 gene as the target gene, constructs L-sgMCT1-Cas9 and L-GFP-sgMCT1-Cas9 recombinant viruses, and downregulates the expression of the MCT1 gene in LCL cells. Therefore, the Cas9 expression vector based on parainfluenza virus PIV5-L constructed in the present invention can achieve effective expression of Cas9 protein; the constructed L-sgRNA-Cas9 and L-GFP-sgRNA-Cas9 integrated systems can achieve efficient delivery and expression of the entire CRISPR system composed of sgRNA and Cas9 genes, thereby achieving the knockout or knockdown effect of the target gene in the target cell. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 Schematic diagram of the structure of inserting GFP and Cas9 into different positions of the PIV5-L genome.
[0019] Figure 2 BHK-optT7 cells were co-transfected with L-Cas9 and L-GFP packaging vectors of different recombinant virus strains.
[0020] Figure 3 Western blotting detection of Vero cells infected with different recombinant virus strains L-Cas9 and L-GFP at different times.
[0021] Figure 4 This is the growth curve of the titer of released subviruses after different recombinant virus strains L-Cas9 and L-GFP infected Vero cells.
[0022] Figure 5 The expression of multiple independent exogenous genes delivered by PIV5-L as a vector. Figure A shows the packaging of L-GFP-Cas9 recombinant virus strain; Figure B shows the protein immunoblotting detection of Vero cells infected by the virus strain.
[0023] Figure 6 Schematic diagram of the genome structure of the L-CRISPR system virus strain targeting MCT and Casp7 based on PIV5-L.
[0024] Figure 7Packaging verification of L-CRISPR system virus strains targeting MCT and Casp7.
[0025] Figure 8 Agarose gel electrophoresis diagram of the amplified gRNA fragments in the genome of the L-CRISPR system virus strain targeting MCT and Casp7.
[0026] Fig. 9 Growth curve determination of L-CRISPR system virus strains targeting MCT and Casp7.
[0027] Fig.10 This is the localization of the Cas9 protein expressed by the L-CRISPR / Cas9 virus strain in Vero cells.
[0028] Fig.11 Northern Blot hybridization detection results of sgRNA expressed by L-CRISPR / Cas9 virus strain.
[0029] Fig.12 Western blot detection of MCT1 and Caspase7 gene editing mediated by L-CRISPR / Cas9 system. DETAILED DESCRIPTION
[0030] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments.
[0031] Plasmid pBS-BSM, plasmid PIV5-L-GFP, BHK-optT7 cells, plasmids lenti-CRISPR-V2-sgCtrl, lenti-CRISPR-V2-sgMCT1, and lenti-CRISPR-V2-sgCasp7 were provided and preserved by the Department of Pathogenic Biology, School of Basic Medical Sciences, Fudan University; B lymphoma cell line DG75 was purchased from American Type Culture Collection [ATCC], Manassas, VA); B lymphoma cell line LCL was provided and preserved by the Department of Pathogenic Biology, School of Basic Medical Sciences, Fudan University; plasmid lenti-CRISPR-V2 was donated by Professor Paul Bates of the University of Pennsylvania.
[0032] Plasmid pBS-BSM, plasmid PIV5-L-GFP, BHK-optT7 cells are disclosed in the literature: Xiaoqing Liu, Lilan Zheng, Ting Wang, A System Based on Novel Parainfluenza Virus PIV5-L for Efficient Gene Delivery of B-Lymphoma Cells. Journal of Virology: 96(8): e0025722.
[0033] The B lymphoma cell line LCL is disclosed in the literature: Xiaohui Mo, Fang Wei, Yin Tong, Lactic Acid Downregulates Viral MicroRNA To Promote Epstein-Barr Virus-Immortalized B Lymphoblastic Cell Adhesion and Growth. Journal of Virology: 92(9): e0033-18.
[0034] The lenti-CRISPR-V2-sgCtrl, lenti-CRISPR-V2-sgMCT1, and lenti-CRISPR-V2-sgCasp7 plasmids are constructed according to the construction method of lentiviral vectors in the prior art and the sgCtrl, sgMCT1, and sgCasp7 sequences in the present application (as shown in SEQ ID NOs.44-46).
[0035] Example 1 Construction of Cas9 expression vector based on parainfluenza virus type 5 L strain PIV5-L
[0036] 1.1 Construction of pB-L-GFP(SH-HN) and pB-L-GFP(△SH) plasmids
[0037] Using plasmid pBS-BSM as a vector and PIV5-L-GFP as a template, the NP, V / P, M, F, SH, EGFP, HN and L genes were connected by segmented cloning. Takara's Primerstar high-fidelity enzyme was used to amplify each required fragment, and each fragment was connected to the vector in a seamless cloning manner. The primer sequences of the amplified fragments are shown in Table 1. PIV5-L-GFP is a full-length plasmid of the PIV5-L genome carrying the GFP gene, named pB-L-GFP (HN-L) in this embodiment.
[0038] Table 1 Primer sequences for the construction of pB-L-GFP(SH-HN) and pB-L-GFP(△SH) plasmids
[0039]
[0040]
[0041] *: The final fragment was obtained by performing overlap PCR on the fragments obtained by PCR with two pairs of primers;
[0042] **: The fragment obtained by PCR with the first pair of primers is used as a template, and the final fragment is obtained by PCR with the second pair of primers.
[0043] PCR system:
[0044]
[0045] Overlap PCR conditions:
[0046]
[0047] The process of connecting the fragments is as follows:
[0048] (1) Construction of plasmid pB-L-NP-P
[0049] SnaBI restriction enzyme digestion pB-BSM to obtain linearized vector, restriction enzyme digestion system:
[0050]
[0051] The NP and V / P fragments obtained by the above PCR were connected to the linearized vector cut with enzymes through seamless cloning technology, followed by transformation. After 16-18 hours, single clone colonies were picked for colony PCR, and 3 positive clones were sent for sequencing.
[0052] (2) Construction of plasmid pB-L-NP-PMF(SH)
[0053] pB-L-NP-P was digested with SnaBI to obtain a linearized vector. The digestion system was the same as (1). The M, F-SH, and SH-Cas9 fragments were linked to the digested vector by seamless cloning. The remaining steps were the same as (1).
[0054] (3) Construction of plasmid pB-L-NP-PMF
[0055] pB-L-NP-P was digested with SnaBI to obtain a linearized vector. The digestion system was the same as (1). The M, F, and F-Cas9 fragments were linked to the digested vector by seamless cloning. The remaining steps were the same as (1).
[0056] (4) Construction of plasmid pB-L-NP-PMF-GFP-HN(SH)
[0057] pB-L-NP-PMF was digested with Sali and SnaBI to obtain a linearized vector. The digestion system was the same as (1). GFP (SH) and HN (SH) fragments were linked to the digested vector by seamless cloning. The remaining steps were the same as (1).
[0058] (5) Construction of plasmid pB-L-NP-PMF-GFP-HN
[0059] pB-L-NP-PMF was digested with Sali and SnaBI to obtain a linearized vector. The digestion system was the same as (1). GFP and HN fragments were linked to the digested vector by seamless cloning. The remaining steps were the same as (1).
[0060] (6) Construction of plasmids pB-L-NP-PMF-GFP-HN-L(SH) and pB-L-NP-PMF-GFP-HN-L
[0061] pB-L-NP-PMF-GFP-HN(SH) and pB-L-NP-PMF-GFP-HN were digested with SnaBI to obtain linearized vectors. The digestion system was the same as (1). L1 and L2 fragments were connected to the digested vectors by seamless cloning. The remaining steps were the same as (1).
[0062] (7) Construction of plasmids pB-L-GFP(SH-HN), pB-L-GFP(△SH)
[0063] pB-L-NP-PMF-GFP-HN-L(SH) and pB-L-NP-PMF-GFP-HN-L were digested with SnaBI to obtain linearized vectors. The digestion system was the same as (1). L3 and L4 fragments were linked to the digested vectors by seamless cloning. The remaining steps were the same as (1).
[0064] 1.2 Construction of pB-L-Cas9(HN-L), pB-L-Cas9(SH-HN), and pB-L-Cas9(△SH) plasmids
[0065] Using pB-L-GFP(HN-L), pB-L-GFP(SH-HN), and pB-L-GFP(△SH) as vectors and lenti-CRISPR-V2 plasmid as template, the GFP in pB-L-GFP(HN-L), pB-L-GFP(SH-HN), and pB-L-GFP(△SH) plasmids was replaced with the Cas9 gene by seamless cloning. The schematic diagram of the viral genome structure is shown in the figure. Figure 1 shown.
[0066] (1) Use 2× PCR which has good fidelity and is suitable for long fragment PCR Max Master Mix (purchased from Vazyme) was used for PCR, and the PCR products were recovered by agarose gel electrophoresis. The primer sequences for the construction of Cas9-related plasmids are shown in Table 2.
[0067] Table 2 Primer sequences for Cas9-related plasmid construction
[0068]
[0069] (2) SalI and NotI were used to digest pB-L-GFP(HN-L), pB-L-GFP(SH-HN), and pB-L-GFP(△SH) to obtain linearized vectors. Enzyme digestion system:
[0070]
[0071] (3) The Cas9 (HN-L), Cas9 (SH-H), and Cas9 (△SH) obtained by the above PCR were connected to the linearized vectors pB-L-GFP (HN-L), pB-L-GFP (SH-HN), and pB-L-GFP (△SH) respectively by seamless cloning technology, and then transformed. After 16-18 hours, single clones were picked for colony PCR, and 3 positive clones were sent for sequencing. The sequencing results showed that the recombinant plasmids pB-L-Cas9 (HN-L), pB-L-Cas9 (SH-HN), and pB-L-Cas9 (△SH) were successfully constructed; the sequence of pB-L-Cas9 (HN-L) is shown in SEQ ID NO.73.
[0072] 1.3pB-L-GFP-Cas9 (HN-L) plasmid construction
[0073] Using the pB-L-GFP (HN-L) genome full-length plasmid as a vector and the lenti-CRISPR-V2 plasmid as a template, the Cas9 gene was linked into pB-L-GFP (HN-L) by seamless cloning. The schematic diagram of the viral genome structure is shown in Figure 1 .
[0074] (1) Use a high fidelity, suitable for long fragment PCR Max Master Mix (purchased from Vazyme) high-fidelity enzyme was used for PCR. Since it was necessary to add the transcription termination start sequence of PIV5 (as shown in SEQ ID NO.75) to the 5' of the Cas9 gene fragment: TTTTAAGAAAAAAGTAGGCCCGGACGGGT, in order to avoid the primer being too long, PCR was performed twice. The amplification primers of the Cas9 gene connected to the transcription termination start sequence of PIV5 are shown in Table 3.
[0075] Table 3 Amplification primers for the Cas9 gene linked to the transcription termination start sequence of PIV5
[0076]
[0077] (2) NotI digested pB-L-GFP(HN-L) to obtain linearized vector, enzyme digestion system:
[0078]
[0079] (3) The fragment 2 obtained by the above PCR was connected to the linearized vector pB-L-GFP (HN-L) by seamless cloning technology, followed by transformation. After 16 to 18 hours, single clones were picked for colony PCR amplification verification, and 3 positive clones were sent for sequencing. The sequencing results showed that the pB-L-GFP-Cas9 (HN-L) plasmid was successfully constructed, and the sequence is shown in SEQ ID NO.74.
[0080] 1.4 Packaging of recombinant virus strains
[0081] BHK-optT7 cells were plated at 0.5 million / well (6-well plate). After 20-24 hours, when the cell confluence reached about 80%-90%, transfection was performed. Fresh 6% FBSDMEM, antibody-free culture medium was used before transfection. The transfection system was as follows:
[0082]
[0083] After the above system is prepared, mix it evenly, leave it at room temperature for 10 minutes, then add it dropwise to the cells in the 6-well plate. After 6-8 hours, replace it with complete medium. Culture it in a 37℃ cell culture incubator and observe it once a day. After 3 days, obvious syncytia can be seen. Figure 2 As shown, it proves that the recombinant virus strain is packaged successfully.
[0084] Collect the virus on the 5th day: add the supernatant of the 6-well plate to a centrifuge tube, centrifuge at 3500 rpm for 10 min, divide the supernatant into aliquots and store at -80°C.
[0085] 1.5 Detection of exogenous gene expression levels in recombinant virus strains at different insertion positions
[0086] The recombinant virus strains with different insertion positions were used to infect Vero cells at an MOI of 0.2, and the cells were harvested 12h, 24h, and 48h after infection to detect protein expression. Figure 3 As shown in the figure, 24 hours after infection, the recombinant virus strains at different insertion positions all expressed Cas9 protein significantly, among which the expression level of L-Cas9(SH-HN) virus was higher than that of L-Cas9(HN-L) and L-Cas9(△SH). 48 hours after infection, the expression level of Cas9 protein in the L-Cas9(△SH) virus group was the highest, followed by the L-Cas9(SH-HN) and L-Cas9(HN-L) virus groups.
[0087] In the case of carrying the short fragment gene GFP, the GFP protein expression level of L-GFP (△SH) virus 48h after infection was also the highest. These results show that the closer the foreign gene is inserted to the 3' end, the higher its expression level, and replacing the virus's SH gene with a foreign gene can significantly increase the expression level of the inserted gene, especially when a longer foreign gene is inserted.
[0088] 1.6 Determination of growth curve of recombinant virus strain
[0089] According to the prior art, the virus titer of the recombinant virus at 0, 12, 24, 48, 72, 96 and 120 h after infection of Vero cells was determined, and a virus growth curve was drawn with time as the horizontal axis and the virus titer in the supernatant as the vertical axis. The results are as follows: Figure 4 As shown in the figure, the recombinant virus strains with different insertion positions, regardless of whether the exogenous gene is a short fragment GFP or a long fragment Cas9, can reach a titer of 10 at 48h after infection. 7 PFU / ml, and there was no significant difference in the growth of recombinant virus strains at different insertion positions, indicating that the different insertion positions of exogenous genes had no significant effect on viral replication and genome stability. The virus titer of L-Cas9(△SH) before 72h was lower than that of L-Cas9(HN-L) and L-Cas9(SH-HN), suggesting that the low expression level of exogenous genes detected by L-Cas9(△SH) infection 48h before infection in the above results may be related to the slow virus replication and packaging speed.
[0090] 1.7 Packaging of L-GFP-Cas9 recombinant virus strain and detection of exogenous gene expression level
[0091] The virus packaging is the same as step 1.3. Figure 5 As shown in A, syncytia can be observed under the microscope three days after transfection, indicating that the virus packaging is successful. The packaged virus strain was then used to infect B lymphoma cell lines DG75 and LCL (MOI = 1), and the protein expression of the exogenous gene was detected 48 hours later. Figure 5As shown in B, Cas9 and GFP proteins were detected 48 hours after infection with the recombinant virus strain, indicating that the L-GFP-Cas9 recombinant virus strain can successfully express GFP and Cas9 proteins independently.
[0092] Example 2 Construction of L-CRISPR / Cas9 system based on PIV5-L
[0093] Since excessive expression of Cas9 protein may increase the risk of non-targeted gene knockout, in this example, sgRNA and Cas9 genes were inserted into the HN-L position to construct a PIV5-L-based L-CRISPR / Cas9 system.
[0094] 2.1 Plasmid construction
[0095] Using pB-L-GFP-Cas9 (HN-L) constructed in step 1.3 of Example 1 as a vector, and using the plasmid lenti-CRISPR-V2-sgCtrl as a template, the GFP gene was replaced by sgCtrl by seamless cloning, or sgCtrl was inserted between the GFP gene and the Cas9 gene (the PIV5 transfer stop-start sequence itself must be connected to the 5' of the sgRNA, as shown in SEQ ID NO.75), and L-sgCtrl-Cas9 and L-GFP-sgCtrl-Cas9 were constructed respectively. According to the same method, using lenti-CRISPR-V2-sgMCT1 and lenti-CRISPR-V2-sgCasp7 plasmids as templates, L-sgMCT1-Cas9, L-GFP-sgMCT1-Cas9, L-sgCasp7-Cas9, and L-GFP-sgCasp7-Cas9 were constructed respectively. The schematic diagram of the genome structure is shown in Figure 6 The sequences of sgCtrl, sgMCT1 and sgCasp7 are shown in Table 4.
[0096] Table 4 Sequences of sgCtrl, sgMCT1 and sgCasp7
[0097]
[0098] (1) PCR to obtain the target fragment
[0099] use Max MasterMix (purchased from Vazyme) high-fidelity enzyme was used for PCR, and the PCR product was recovered by agarose gel electrophoresis and confirmed to be single band using PCR Clean-Up Kit (DP04-300, GeneMark). The primer sequences for L-CRISPR related plasmid construction are shown in Table 5.
[0100] Table 5 Primer sequences for L-CRISPR related plasmid construction
[0101]
[0102] (2) Enzyme digestion
[0103] pB-L-GFP-Cas9(HN-L) was digested with Sali, NotI and NotI to obtain two linearized vectors. The digestion system was:
[0104]
[0105] (3) Connection
[0106] The three fragments sgCtrl, sgMCT1, and sgCaspase7 obtained by the above PCR were connected into the linearized vector of pB-L-GFP-Cas9 (HN-L) digested with Sali and NotI by seamless cloning technology, followed by transformation. After 16-18 hours, single clone colonies were picked for colony PCR, and three positive clones were sent for sequencing to obtain plasmids L-sgCtrl-Cas9, L-sgMCT1-Cas9, and L-sgCasp7-Cas9.
[0107] The three fragments GFP-sgCtrl, GFP-sgMCT1, and GFP-sgCaspase7 obtained by the above PCR were connected into the linearized vector of NotI-digested pB-L-GFP-Cas9(HN-L) through seamless cloning technology, followed by transformation. After 16-18 hours, single clone colonies were picked for colony PCR, and three positive clones were sent for sequencing to obtain plasmids L-GFP-sgCtrl-Cas9, L-GFP-sgMCT1-Cas9, and L-GFP-sgCasp7-Cas9.
[0108] 2.2 Virus packaging and protein expression verification
[0109] The virus packaging step is the same as step 1.3 of Example 1. Three days after transfection, syncytia can be observed in BHK-optT7 cells ( Figure 7 ), which preliminarily indicated that the recombinant virus strain was successfully packaged. Specific primers for different sgRNAs were designed (Table 6), and PCR analysis was performed on the viral RNA extracted from the viral supernatant. Figure 8 As shown in the figure, the corresponding sgRNA fragments can be detected in different recombinant virus strains, indicating that the rescued recombinant virus strains can stably carry the sgRNA gene. By measuring the virus titer and drawing the virus growth curve, it can be found that there is no significant difference in the growth of different recombinant virus strains compared with the wild strain ( Fig. 9). These results indicate that PIV5-L can successfully carry the integrated CRISPR system without significantly affecting viral replication.
[0110] Table 6 Primer sequences used for genome detection of L-CRISPR recombinant virus strains
[0111]
[0112] Laser confocal microscopy was used to detect the localization of the Cas9 protein expressed by the L-CRISPR / Cas9 recombinant virus strain in cells. Fig.10 As shown in the figure, like the L-Cas9 virus, the Cas9 protein expressed by the L-sgCtrl-Cas9 and L-GFP-sgCtrl-Cas9 viruses was mainly localized in the nucleus 48 hours after infection. The above results show that the L-CRISPR / Cas9 recombinant virus strain constructed based on PIV5-L can stably carry the CRISPR system and effectively express the Cas9 protein without affecting the normal growth of the virus.
[0113] 2.3 Verification of gene editing effects by L-CRISPR / Cas9 system
[0114] (1) Detect the transcription of sgRNA in L-sgCtrl-Cas9 and L-GFP-sgCtrl-Cas9 recombinant virus strains by Northern Blot. Fig.11 As shown, sgCtrl can be detected only in cells infected with L-sgCtrl-Cas9 and L-GFP-sgCtrl-Cas9 recombinant virus strains, while no sgCtrl transcripts are detected in cells infected with mock and L-GFP recombinant viruses, and the expression level of sgCtrl increases with the increase of MOI, indicating that sgRNA can be effectively expressed in both L-sgCtrl-Cas9 and L-GFP-sgCtrl-Cas9 recombinant viruses.
[0115] (2) Verify the constructed knockout system L-CRISPR / Cas9 at the cell level. LCLs were infected with a recombinant virus strain targeting the MCT1 gene, and the cells were collected 3 days after infection to detect the expression level of MCT1 protein. Fig.12 As shown in the figure, compared with the uninfected group and the recombinant virus strain carrying sgCtrl, the expression level of MCT1 protein decreased significantly after infection with the recombinant virus strain carrying sgMCT1, indicating that the CRISPR system targeting the MCT1 gene constructed based on PIV5-L can play a certain gene knockout role. At the same time, the recombinant virus strain targeting the Caspase7 gene was used to infect the B lymphoma cell line DG75, and the cells were collected 3 days after infection to detect protein expression. Fig.12 As shown, in the DG75 cell line, the expression level of Caspase7 protein was significantly reduced in the group infected with the virus carrying sgCaspase7.
[0116] The specification and drawings of the present invention are considered to be illustrative rather than restrictive. On the basis of the present invention, those skilled in the art can make some substitutions and modifications to some of the technical features according to the disclosed technical content without creative labor, all of which are within the protection scope of the present invention.
Claims
1. A Cas9 expression vector based on parainfluenza virus type 5 L strain PIV5-L, characterized in that: The Cas9 expression vector is the recombinant plasmid pB-L-Cas9 (HN-L), and the sequence is shown in SEQ ID NO.
73.
2. The Cas9 expression vector according to claim 1, characterized in that It also contains a GFP gene, and the Cas9 expression vector is a recombinant plasmid pB-L-GFP-Cas9 (HN-L), and the sequence is shown in SEQ ID NO.
74.
3. An L-CRISPR / Cas9 system based on parainfluenza virus type 5 L strain PIV5-L, characterized in that: It comprises an sgRNA targeting a target gene and the Cas9 expression vector as claimed in claim 1 or 2.
4. The use of the L-CRISPR / Cas9 system as claimed in claim 3 in constructing gene knockout cells, characterized in that: The sgRNA targeting the target gene was inserted between the HN gene and the L gene of the Cas9 expression vector by seamless cloning to construct the recombinant plasmid L-sgRNA-Cas9 or L-GFP-sgRNA-Cas9; the recombinant plasmid L-sgRNA-Cas9 or L-GFP-sgRNA-Cas9 was transfected into BHK-optT7 cells to complete the packaging of the recombinant virus; the target cells were infected with the packaged recombinant virus to deliver the CRIPSR system and knock out the target gene in the target cell.
5. The use according to claim 4, characterized in that: The sgRNA is sgCasp7; the sgCasp7 targets the Caspase7 gene in the B lymphoma cell line DG75; the sequence of the sgCasp7 is shown in SEQ ID NO.
46.
6. The use according to claim 4, characterized in that: The sgRNA is sgMCT1; the sgMCT1 targets the MCT1 gene in the B lymphoma cell line LCL; the sequence of the sgMCT1 is shown in SEQ ID NO.
45.
7. The use according to claim 4, characterized in that: Using pB-L-GFP-Cas9 (HN-L) as a vector, the GFP gene was replaced by sgRNA through seamless cloning to construct the recombinant plasmid L-sgRNA-Cas9.
8. The use according to claim 4, characterized in that: Using pB-L-GFP-Cas9 (HN-L) as a vector, sgRNA was inserted between the GFP gene and the Cas9 gene by seamless cloning to construct the recombinant plasmid L-GFP-sgRNA-Cas9.
9. The use according to claim 8, characterized in that: The 5' end of the sgRNA is connected to the transcription termination start sequence of PIV5, and the transcription termination start sequence of PIV5 is shown in SEQ ID NO.75.
Citation Information
Patent Citations
B-philic cell expression delivery system as well as construction method and application thereof
CN116769826A
